Emerging excipients in parenteral medications: The new paradigm

Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems

Volumn , Issue , 2006, Pages 357-372

  Apte, Shireesh P ^a   Ugwu, Sydney O ^b  

^a Chemologic LLC NA   (United States)

^b NeoPharm Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952080085     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (86)

1. Lee J, Park YS, Kim YI, et al. Synthesis of a porphyrin having eight carborane cages. Bull Korean Chem Soc 1999; 20(11): 1371-1372.
2. Smith GK, Banks S, Blumenkopf TA, et al. Toward antibody directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate. J Biol Chem 1997; 272(25): 15804-15816.
3. Vector consisting of a transcriptional regulatory DNA sequence linked to a DNA sequence encoding β-lactamase for enzyme prodrug therapy. Glaxo Wellcome, Inc., Research Triangle Park, NC. Patent No. WO9719180A2, issued 5-29-97.
4. Kukowska-Latallo JF, Chen C, Eichman J, et al. Enhancement of dendrimer-mediated transfection using synthetic lung surfactant exosurf neonatal in vitro. Biochem Biophys Res Commun 1999; 264(1): 253-261.
5. Baeuerle PA, Kufer P, Lutterbuse R. Bispecific antibodies for polyclonal T-cell enlargement. Curr Op Mol Ther 2003; 5(4): 413-419.
6. Oldenburg SJ, Jackson JB, Westcott JB, Halas NJ. Infrared extinction properties of gold nanoshells. Appl Phys Lett 1999; 75(19): 2897-2899.
7. Hirsch LR, Sershen SR, Halas NJ, Stafford RJ, Hazle J, West JL. Nanoshell mediated near infrared photothermal tumor therapy. 2003 Summer Bioengineering Conference, June 25-29, Key Biscayne, FL.
8. Unger E, Matsunaga TO, Schumann PA, Zutshi R. Microbubbles in molecular imaging and therapy. Medicamundi 2003; 47(1): 58-62.
9. Calcium Disodium Versenate. 3M Pharmaceuticals, Patient package insert.
10. Exosurf® Neonatal for intratracheal suspension. Glaxo Wellcome, Research Triangle Park, NC.
11. Supervent® Aerosol. Discovery Laboratories Inc., Doylestown, PA.
12. Orthovisc®. Anika Therapeutics, Woburn, MA.
13. Viscoat®, Provisc®. Alcon Inc., Fort Worth, TX.
14. Compositions and methods for nucleic acid delivery to the lung. Inhale Therapeutic Systems Inc., San Carlos, CA. U.S. Patent No. 5994314, issued 11-30-1999.
15. Cyclokapron®. Kabi Pharmacia, Patient package insert.
16. Pharmaceutical preparations containing plasminogen activators. Boehringer Mannheim Gmbh, Mannheim, Germany. U.S. Patent No. 5747030, issued 8-21-96.
17. Solutol® HS 15. BASF Aktiengesellschaft, 2002.
18. Dintaman JM, et al. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999; 16(10): 1550-1556.
19. Coon JS, et al. Cancer Res 1991; 51(3): 897-902.
20. Method for antibody targeting of therapeutic agents. Immunomedics, Inc., Morris Plains, NJ. U.S. Patent No. 5851527, issued 12-22-98.
21. Hallahan DE, Mauceri HJ, Seung LP, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1(8): 786-791.
22. Ros TD, Spalluto G, Prato M. Biological applications of fullerene derivatives: a brief overview. Croat Chem Acta 2001; 74(4): 743-755.
23. Slovin SF, Ragupathi G, Adluri S, et al. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci USA 1999; 96: 5710-5715.
24. Ivics Z, Hackett PB, Plasterk RH, et al. Cell 1997; 91: 501-510.
25. Holle L, Song W, et al. A matrix metalloproteinase 2 cleavable melittin/avidin conjugate specifically targets tumor cells in vitro and in vivo. Int J Oncol 2003; 22: 93-98.
26. Cunningham C, Nemunaitis J. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Human Gene Ther 2001; 12(12): 1594-1596.
27. Levin M, Quint PA, Goldstein B, et al. Recombinant rBPI21 as adjunctive treatment for children with severe meningococcal sepsis: a randomized trial. RBPI Meningococcal sepsis study group. Lancet 2000; 356(9234): 961-967.
28. Kohler U, Ayre BG, Goodman HM, et al. Trans-splicing ribozymes for targeted gene delivery. J Mol Biol 1999; 285: 1935-1950.
29. Cortes ML, deFelipe P, et al. Successful use of a plant gene in the treatment of cancer in vivo. Gene Ther 1998; 5(11): 1499-1507.
30. Shmulevitz M, Duncan R. A new class of fusion-associated small transmembrane (FAST) proteins encoded by the non-enveloped fusogenic reoviruses. EMBO J 2000; 19(5): 902-912.
31. Ogris M, Carlisle RC, et al. Melittin enables efficient vesicular escape and enhanced nuclear access of nonviral gene delivery vectors. J Biol Chem 2001; 276(50): 47550-47555.
32. Visudyne®. Novartis Ophthalmics Inc., Duluth, GA and Photofrin®. Axcan Scandipharm Inc., Birmingham, AL.
33. Cagle DW, Kennel SJ, Mirzadeh S, et al. In vivo studies of fullerene based materials using endohedral metallofullerene radiotracers. Proc Natl Acad Sci USA 1999; 96: 5182-5188.
34. Apte SP, Ugwu SO. A review and classification of emerging excipients in parenteral medications. Pharm Technol 2003.
35. Shinkai M, Suzuki M, Iijima S, et al. Antibody-conjugated magnetoliposomes for targeting cancer cells and their application in hyperthermia. Biotechnol Appl Biochem 1994; 21: 125-137.
36. So H-S, et al. Effect of a novel saponin adjuvant derived from Quillaja saponaria on the immune response to recombinant Hepatitis B surface antigen. Mol Cells 1996; 7(2): 178-186.
37. A component of Theratope® vaccine in phase III clinical trials for use against metastatic breast cancer. Biomira Inc., Edmonton, Canada.
38. Corixa Corporation. Seattle, WA.
39. MDX-RA®, an immunotoxin conjugated to an antibody designed to prevent secondary cataracts, phase III clinical trials, enrollment stopped. Medarex, Annandale, NJ.
40. Allison AC. Squalene and squalane emulsions as adjuvants. Methods (Duluth) 1999; 19(1): 87-93.
41. Pillion DJ, et al. Structure-function relationship among Quillaja Saponins serving as excipients for nasal and ocular delivery of insulin. J Pharm Sci 1996; 85(5): 518-524.
42. Abbokinase® (Urokinase for injection). Abbott Laboratories, Abbott Park, IL. Acthar Gel® (Corticotropin injection). Rhone Poulanc Rorer, Collegeville, PA.
43. Solganol® (Aurothioglucose suspension). Schering Plough Corp., Madison, NJ.
44. Angelova MI, et al. Interactions of DNA with giant liposomes. Chem Phys Lipids 1999; 101(1): 123-137.
45. Allen TM, et al. Biochim Biophys Acta 1990; 1029: 91-97.
46. Walker S, et al. Cationic facial amphiphiles: a promising class of transfection agents. Proc Natl Acad Sci USA 1996; 93: 1585-1590.
47. Patent # WO9529186. University of Princeton, 1996.
48. Awasthi S, et al. Inhibition of liposomal lipid peroxidation by spermidine. J Microencapsulation 1992; 9(2): 237-242.
49. Hays LM, et al. Antifreeze glycoproteins inhibit leakage from liposomes during thermotropic phase transitions. Proc Natl Acad Sci USA 1996; 93: 6835-6840.
50. Sphingosomes for enhanced drug delivery. Inex Pharmaceuticals Corp., Canada. U.S. Patent # 5741516, issued 4-21-1998.
51. De La Maza A, et al. Biopolymer excreted by Pseudoalteromonas antarctica NF3, as a coating and protective agent of liposomes against dodecyl maltoside. Biopolymers 1999; 50(6): 5795-5788.
52. Chen J, et al. Galactosylated histone mediated gene transfer and expression. Human Gene Ther 1994; 5: 429-435.
53. Zhang MZ, et al. A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor. Pharm Res 1995; 12(10): 1447-1452.
54. Chong MW, et al. Stabilizers against heat-induced aggregation of RPR 114849, an acidic fibroblast growth factor (aFGF). Int J Pharmaceut 1998; 167: 25-36.
55. Vucenik I, et al. Novel anticancer function of inositol hexaphosphate: inhibition of human rhabdomyosarcoma in vitro and in vivo. Anticancer Res 1998; 18(3A): 1377-1384.
56. Natural polymers as contrast media for magnetic resonance imaging. ImaRx Pharmaceutical Corp., Tucson, AZ. U.S. Patent # 5368840, issued 11-29-94.
57. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability. Alkermes, Inc., Cambridge, MA. U.S. Patent # 5112596, issued 5-12-92.
58. Emerich DF, et al. Enhanced delivery of carboplatin into brain tumors with intravenous Cereport® (RMP-7): dramatic differences and insight gained from dosing parameters. Br J Cancer 1999; 80(7): 964-970.
59. Cloughesy TF, et al. Intra-arterail Cereport® (RMP-7) and Carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurgery 1999; 44(2): 270-278.
60. Pharmaceutical formulation. Supergen Inc., San Ramon, CA. U.S. Patent # 5804568, issued 9-9-98. NDA filed for MitoExtra®, a proprietary reformulation of the anti-cancer drug, Mitomycin.
61. Fluorocyclosaccharide drug delivery systems. University of Alberta, Edmonton, CA. U.S. Patent # 5739121, issued 4-14-98.
62. Khan MAS, et al. Molecular mechanism of the excellent emulsifying properties of phosvitin- galactomannan conjugate. J Agric Food Chem 1999; 47(6): 2262-2266.
63. Dipyridoxyl phosphate NMRI contrast agent compositions. Salutar, Inc., Sunnyvale, CA. U.S. Patent # 5091169, issued 2-25-92.
64. Marafie, et al. Complexes of vitamin B6 XX: equilibrium and mechanistic studies of the reaction of pyridoxal-5′-phosphate with pyridoxamine-5′-phosphate in the presence of copper(II). J Inorg Biochem 1989; 37: 7-16.
65. Matsushima, et al. N-Pyridoxylidenehydrazine-N′, N′-diacetic acid. III. Formation of metal chelates in solution. Chem Pharm Bull 1989; 35(12): 4695-4699.
66. Soltes L, et al. Cyclodextrin derivative of hyaluronan. Carbohydr Polym 1999; 39(1): 17-24.
67. Li JY, et al. Genetically engineered brain drug delivery vectors: cloning, expression and in vivo application of an anti-transferrin receptor single chain antibody-streptavidin fusion gene and protein. Protein Eng 1999; 12(9): 787-796.
68. Penichet ML, et al. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. J Immunol 1999; 163(8): 4421-4426.
69. Portnoy, et al. Capacity of listeriolysin O, streptolysin O and perfringolysin O to mediate growth of Bacillus subtilis within mammalian cells. Infect Immun 1992; 60: 2710-2717.
70. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells. University of Connecticut, Storrs, CT and Targetech, Inc. a wholly owned subsidiary of the Immune Response Corporation, Carlsbad, CA. U.S. Patent # 5728399, issued 3-17-88.
71. Wagner E, et al. DNA-binding transferrin conjugates as functional gene delivery agents. Bioconjug Chem 1991; 2: 226-231.
72. Quilimmune-M®. Malaria vaccine adjuvant, phase I trials completed. Aquila Biopharmaceuticals Inc., Framingham, MA.
73. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: unrestricted delivery into all cells?. Trends Cell Biol 2000; 10: 290-295.
74. Cotton M, et al. Transferrin-polycation mediated introduction of DNA into leukemic cells. Proc Natl Acad Sci USA 1990; 87: 4033-4037.
75. Zatloukal K, et al. Somatic gene therapy for cancers: the utility of transfer infection in generating tumor vaccines. Gene 1993; 135: 199-207.
76. Poul MA, et al. Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol 1999; 288(2): 203-211.
77. Bayley H. Building doors into cells. Sci Am 1997: 62-67.
78. Namba Y, et al. Liposomal modification with uronate, which endows liposomes with long circulation in vivo, reduces the uptake of liposomes by J774 cells in vitro. Life Sci 1992; 50(23): 1773-1779.
79. Abelcet®, amphotericin lipid complex injection. Liposome Co., Princeton, NJ.
80. Ambisome®, Daunoxome®, liposomal amphotericin B and daunorubicin citrate injection. Liposomal lurtotecan in phase I clinical trials. Gilead Sciences Inc., Foster City, CA.
81. Barth RF. A critical assessment of boron neutron capture therapy: an overview. J Neuro Oncol 2003; 62: 1-5.
82. McFadden DW, Riggs DR, Jackson BJ, et al. Keyhole limpet hemocyanin, a novel immune stimulant with promising anticancer activity in Barrett’s esophageal adenocarcinoma. Am J Surg 2003; 186(5): 552-555.
83. Zhang L, Sanker U, Lampe DJ, et al. The Himar1 mariner transposase cloned in a recombinant adenovirus vector is functional in mammalian cells. Nucleic Acids Res 1998; 26(16): 3687-3693.
84. Ma Z, Taylor JS. Nucleic acid triggered catalytic drug release. PNAS 2000; 97(21): 11159-11163.
85. Nantz M, Zhu J. Ortho ester lipids. U.S. Patent No. 6200599, 2001.
86. Gomez JDF, Sansom MSP. Acquisition of siderophores in gram negative bacteria. Nature Rev Mol Cell Biol 2003; 4: 105-116.